Sign In
Buy CUE
$26.91
-1.71 (-5.97%)
At Close: Jun 03, 2026
The Daily Biotech Pulse: Mixed Filgotinib Readout For Gilead-Galapagos, Akorn To File For Chapter 11, D-Day For Aquestive
12:00am, Thursday, 21'st May 2020
Here's a roundup of top developments in the biotech space over the last 24 hours:
Scaling The Peaks
(Biotech stocks that hit 52-week highs on May 20.)
ADC Therapeutics SA (...
Cue Biopharma Reports First Quarter 2020 Results, Updates of CUE-101 Phase 1 Dose Escalation Study and Recent Business Highlights
09:01pm, Tuesday, 19'th May 2020
CAMBRIDGE, May 19, 2020 (GLOBE NEWSWIRE via COMTEX) -- Cue Biopharma, Inc. (NASDAQ: CUE), a clinical-stage biopharmaceutical company engineering a novel...
Cue Biopharma Reports First Quarter 2020 Results, Updates of CUE-101 Phase 1 Dose Escalation Study and Recent Business Highlights
08:01pm, Tuesday, 19'th May 2020
CAMBRIDGE, Mass., May 19, 2020 -- Cue Biopharma, Inc. (NASDAQ: CUE), a clinical-stage biopharmaceutical company engineering a novel class of injectable biologics to selectively.
Cue Biopharma to Present at AACR Virtual Annual Meeting
12:00pm, Monday, 18'th May 2020
Cue Biopharma, Inc. (CUE), a clinical-stage biopharmaceutical company engineering a novel class of injectable biologics to selectively engage and modulate targeted T cells within the body, announced t
Cue Biopharma Announces Strategic Research Collaboration with Dr. Michael Dustin and Oxford University
12:00pm, Thursday, 14'th May 2020
Cue Biopharma, Inc. (CUE), a clinical-stage biopharmaceutical company engineering a novel class of injectable biologics to selectively engage and modulate targeted T cells within the body, announced t
Cue Biopharma to Host Business Update Call and Webcast
12:00pm, Tuesday, 12'th May 2020
Cue Biopharma, Inc. (CUE), a clinical-stage biopharmaceutical company engineering a novel class of injectable biologics to selectively engage and modulate targeted T cells within the body, announced t
Here's a roundup of top developments in the biotech space over the last 24 hours:
Scaling The Peaks
(Biotech Stocks Hitting 52-week Highs May 11)
Acceleron Pharma Inc (NASDAQ...
Cue Biopharma, Inc. (CUE) Expected to Beat Earnings Estimates: What to Know Ahead of Q1 Release
04:30pm, Wednesday, 06'th May 2020
Cue Biopharma, Inc. (CUE) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
The Daily Biotech Pulse: FDA Nod For GlaxoSmithKline, Hologic To Launch Coronavirus Test, Amarin's Strong Q1
11:19am, Thursday, 30'th Apr 2020
Here's a roundup of top developments in the biotech space over the last 24 hours.Scaling The Peaks (Biotech Stocks Hitting 52-week Highs April 29)• Arvinas Inc (NASDAQ: ARVN) • Biondvax Pharmaceu
The Daily Biotech Pulse: FDA Nod For GlaxoSmithKline, Hologic To Launch Coronavirus Test, Amarin's Strong Q1
12:00am, Thursday, 30'th Apr 2020
Here's a roundup of top developments in the biotech space over the last 24 hours.
Scaling The Peaks
(Biotech Stocks Hitting 52-week Highs April 29)
• Arvinas Inc (NASDAQ...
Dynamic New Players Gain Momentum In Digital, Data And Patient-Centric Space
02:04pm, Tuesday, 28'th Apr 2020
Not only vaccines-oriented pharma, teleworking, or food delivery companies draw the attention of investors. By the same token, COVID-19 is not the only virus on
Zacks.com featured highlights include: ThermoGenesis, 21Vianet, Livongo Health, Cue Biopharma and Sharps Compliance
02:02pm, Monday, 27'th Apr 2020
Zacks.com featured highlights include: ThermoGenesis, 21Vianet, Livongo Health, Cue Biopharma and Sharps Compliance
Zacks.com featured highlights include: ThermoGenesis, 21Vianet, Livongo Health, Cue Biopharma and Sharps Compliance
02:02pm, Monday, 27'th Apr 2020
Zacks.com featured highlights include: ThermoGenesis, 21Vianet, Livongo Health, Cue Biopharma and Sharps Compliance
Cue Biopharma (NASDAQ:CUE) Upgraded by BidaskClub to "Strong-Buy"
10:06am, Saturday, 25'th Apr 2020
Cue Biopharma (NASDAQ:CUE) was upgraded by equities research analysts at BidaskClub from a “buy” rating to a “strong-buy” rating in a research note issued to investors on Saturday, BidAskClub
The Zacks Analyst Blog Highlights: Cue Biopharma, PJT Partners, Avenue Therapeutics, SpartanNash and Gaia
03:07pm, Friday, 24'th Apr 2020
The Zacks Analyst Blog Highlights: Cue Biopharma, PJT Partners, Avenue Therapeutics, SpartanNash and Gaia
